CoChat
Sign Up
Cited by 6Lipoproteins and Cardiovascular HealthLipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Efficacy and safety of Olezarsen in treating hypertriglyceridemia: a systematic review and meta-analysis of randomized controlled trials

Open access
Saddique, Muhammad Nabeel, Thapa, Rukshar, Khan, Yaseen, Javaid, Hammad, Khawar, Muhammad Muneeb, Rehman, Abdur, Dave, Rishita, Raval, Rutvik +8 more·2025·Discover Medicine
DOI 10.1007/s44337-025-00329-2
Open this paper in CoChat — free accountOpen PDF

Abstract

Hypertriglyceridemia is a major risk factor for cardiovascular disease and remains poorly managed in high-risk individuals despite existing treatments. Olezarsen, a novel antisense oligonucleotide targeting Apo C-III, has shown reduction in triglyceride levels and potentially reducing cardiovascular risk in hypertriglyceridemia patients. To assess the efficacy and safety of Olezarsen in treating hypertriglyceridemia. A comprehensive search was conducted through PubMed, Cochrane, Embase, Scopus, and ClinicalTrials.gov databases from inception till July 16, 2024. This review included RCTs involving adults (18–65 years) with moderate to severe hypertriglyceridemia (TAG ≥ 200 mg/dL). The dichotomous outcomes were pooled as risk ratio (RR) and continuous outcomes represented as mean % change from baseline with 95% confidence intervals (CI) using the random-effects model. The I 2 and X 2 statistics were employed to evaluate interstudy heterogeneity. All the calculations were performed using RevMan 5.4 and OpenMeta. A p-value of < 0.05 was indicative of statistical significance. This meta-analysis included 4 RCTs with 202 patients. We found a significant mean % change for -65.38% Apo-CIII levels (95% CI − 75.00 to − 55.55, p = 0.000, I 2 = 99.7%), − 44.64% TAGS (95% CI − 55.635 to − 33.649, p = 0.000, I 2 = 99.53%), −14.81% Apo-B (95% CI − 22.05 to − 7.57, p = 0.000, I 2 = 99.39%), 38.85% HDL (95% CI 27.688 to 50.042, p = 0.000, I 2 = 99.55%), and -8.84% total cholesterol (95% CI − 11.483 to − 6.203, p = 0.000, I 2 = 94.92%) from baseline versus placebo. We found reduced risk of any adverse events (RR 0.96, 95% CI 0.87–1.05, p = 0.34 I 2 = 0%), any serious adverse events (RR 0.94, 95% CI 0.44–2.03, p = 0.88, I 2 = 34%) and hypersensitivity reaction (RR 0.65, 95% CI 0.20–2.08, p = 0.47, I 2 = 12%) in Olezarsen group as compared to placebo. Olezarsen is proved to be effective in managing hypertriglyceridemia patients with no significant adverse events. The small sample size and high heterogeneity undermine our findings and more robust studies with larger sample sizes are required to evaluate its full potential.

AI snapshot

Written from the paper’s full text.

TL;DR

This systematic review and meta-analysis of 4 RCTs found Olezarsen significantly reduced Apo-CIII, triglycerides, and other lipid parameters versus placebo, with no significant increase in overall adverse events. However, high heterogeneity and small sample size limit confidence in the findings.

Key findings

  • Olezarsen produced significant mean % changes from baseline versus placebo: Apo-CIII −65.38% (95% CI −75.00 to −55.55, p = 0.000, I² = 99.7%), TAG −44.64% (95% CI −55.635 to −33.649, p = 0.000, I² = 99.53%), Apo-B −14.81% (95% CI −22.05 to −7.57, p = 0.000, I² = 99.39%), HDL +38.85% (95% CI 27.688 to 50.042, p = 0.000, I² = 99.55%), and total cholesterol −8.84% (95% CI −11.483 to −6.203, p = 0.000, I² = 94.92%).
  • Additional reported efficacy outcomes included VLDL −47.61% (95% CI −50.57 to −44.65, I² = 89.87%), non-HDL −20.74% (95% CI −25.36 to −16.13, I² = 98.78%), and LDL −2.25% (95% CI −12.649 to 8.146, I² = 98.66%).
  • Patients achieving normal TAG levels (<200 mg/dL) after 6 months were significantly more frequent with Olezarsen: RR 7.90 (95% CI 4.35–14.35, I² = 0%, p < 0.00001).
  • Safety outcomes showed no significant difference for any adverse events (RR 0.96, 95% CI 0.87–1.05, p = 0.34, I² = 0%), any serious adverse events (RR 0.94, 95% CI 0.44–2.03, p = 0.88, I² = 34%), or hypersensitivity reaction (RR 0.65, 95% CI 0.20–2.08, p = 0.47, I² = 12%); renal adverse events were significantly reduced with Olezarsen (RR 0.33, 95% CI 0.12–0.90, p = 0.03, I² = 0%).

Methods

  • Systematic review and meta-analysis of randomized controlled trials, reported per PRISMA and conducted according to the Cochrane Handbook.
  • Searched PubMed, Embase, Scopus, Cochrane, and ClinicalTrials.gov from inception to July 16, 2024; included adults 18–65 years with moderate to severe hypertriglyceridemia (fasting TAG ≥ 200 mg/dL). Four RCTs were included, with 202 vs 172 patients in Olezarsen and placebo groups respectively (the discussion reports 298 total participants).
  • Dichotomous outcomes pooled as risk ratios (RR) and continuous outcomes as mean % change from baseline with 95% CIs using random-effects models; heterogeneity assessed with I² and χ²; analyses performed in RevMan 5.4 and OpenMeta; risk of bias assessed with RoB 2.0.

Limitations

  • Stated by the paper: small sample size of included studies limits reliability and generalizability; high heterogeneity undermines findings; treatment adherence, patient compliance, and cost-effectiveness were not addressed; cardiovascular outcomes, FCS/pancreatitis risk, and long-term side effects of prolonged use were not assessed.
  • Evident from the text: the abstract states “4 RCTs with 202 patients,” while the results and discussion describe 202 vs 172 patients and 298 total participants, indicating inconsistent reporting of the analyzed population.
  • Evident from the text: funnel plots were not used for publication bias because the recommended minimum of 10 studies per outcome was not reached.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s44337-025-00329-2

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

8 of 16 cited sources checked · 1 supported · 0 flagged · accuracy not yet measured

  • Premisecitation

    The targeted delivery of Olezarsen to hepatocytes reduces hypertriglyceridemia more effectively than current medications.

    “The targeted delivery of the olezarsen to the hepatocyte reduces hypertriglyceridemia more effectively than current medications [8,9].”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites [8] Gaudet D, Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S, et al. RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia. NEJM Evid. 2023. https://doi.org/10.1056/EVIDoa2200325. source
    • cites [9] Kolovou G, Kolovou V, Katsiki N. Volanesorsen: a new era in the treatment of severe hypertriglyceridemia. J Clin Med. 2022;11:982. https://doi.org/10.3390/jcm11040982. source

      The Case Presentation and Expert Opinion discuss triglyceride reductions with volanesorsen, not olezarsen. Searches for olezarsen and hepatocyte-targeted delivery found no passage addressing olezarsen’s delivery or comparing its effectiveness with current medications. (LLM, conf=0.76)

      Experimental — accuracy not yet measured
  • Interpretationcitation

    Olezarsen has a more favorable side effect profile compared to Volanesorsen.

    “Olezarsen also shows a more favorable side effect profile compared to its predecessor, Volanesorsen.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [9] Kolovou G, Kolovou V, Katsiki N. Volanesorsen: a new era in the treatment of severe hypertriglyceridemia. J Clin Med. 2022;11:982. https://doi.org/10.3390/jcm11040982. source

      Section 2.2 (page not provided) reports injection-site reactions and thrombocytopenia among volanesorsen-treated patients, supporting the side-effect concern about that drug. The copy does not report olezarsen safety or compare the two drugs, so it does not establish that olezarsen has a more favorable side-effect profile. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
    • Rests on an assumption: Olezarsen has a relatively better safety profile with no major adverse events compared to Volanesorsen.
  • Findingown data

    Olezarsen reduced Apo-CIII levels by a mean of -65.38% from baseline versus placebo (95% CI -75.00 to -55.55/55.77, p=0.000, I2=99.7%).

    “We found a significant mean % change for -65.38%Apo-CIII levels (95% CI -75.00 to -55.55, p = 0.000, I 2 = 99.7%)”
    • Also stated in: § 3.16 Change in mean % apolipoprotein C-III (Apo-C III) · plain
      “We found a significant mean % change of -65.38%APO C-III (95% CI -75.00 to -55.77%,I 2 = 99.7%,P = 0.000)”
    Quote in the paperSubstantial claim
  • Findingown data

    There is no difference in risk of GFR reduction >25% between Olezarsen and placebo (RR 0.69, 95% CI 0.44-1.10, I2=0%, P=0.12).

    “we found that there is no difference of risk of GFR reduction in the Olezarsen group (RR 0.69, 95% CI 0.44-1.10,I 2 = 0%, P = 0.12) between two groups”
    Quote in the paperSubstantial claim
  • Findingown data

    Olezarsen reduced total cholesterol by a mean of -8.84% from baseline versus placebo (95% CI -11.483 to -6.203, p=0.000, I2=94.92%).

    “We found a significant mean % change of -8.84%Total Cholesterol (95% CI -11.483 to -6.203%,I 2 = 94.92%,P = 0.000)”
    Quote in the paperSubstantial claim
  • May combine two claims. 16
  • Classified as probably not a substantial claim. 5

  • May combine two claims.

    Premisecitation

    Despite advancements in dyslipidemia management, many individuals with hypertriglyceridemia remain inadequately managed, particularly those at high cardiovascular risk.

    “Despite advancements in dyslipidemia management, many individuals with hypertriglyceridemia remain inadequately managed, particularly those at high cardiovascular risk who demand more aggressive therapeutic strategies [3].”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [3] Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999–3058. https://doi.org/10.1093/eurheartj/ehw272. source

      Section 7.3 (p. 33) recommends considering drug treatment for high-risk patients with elevated triglycerides, supporting the need for additional treatment in some cases. It does not establish that many people with hypertriglyceridaemia are inadequately managed, and its recommendations are conditional rather than a general call for more aggressive treatment. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Pharmacological therapies such as fibrates, statins, niacin, and omega-3 fatty acids, as well as lifestyle adjustments, are currently available therapeutic options for controlling hypertriglyceridemia, but often have drawbacks regarding effectiveness, tolerability, and ability to significantly reduce triglyceride levels necessary to lower cardiovascular risk.

    “Pharmacological therapies such as fibrates, statins, niacin, and omega-3 fatty acids, as well as lifestyle adjustments, are currently available therapeutic options for controlling hypertriglyceridemia. Nevertheless, these therapies often have drawbacks regarding their effectiveness, tolerability, and ability to significantly reduce triglyceride levels necessary to lower cardiovascular risk [4,5].”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [4] Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Stalenhoef A. Treatment options for hypertriglyceridemia: From risk reduction to pancreatitis. Best Pract Res Clin Endocrinol Metab. 2014;28:423–37. https://doi.org/10.1016/j.beem.2013.10.002. source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured
    • cites [5] Gouni-Berthold I, Schwarz J, Berthold HK. Updates in drug treatment of severe hypertriglyceridemia. Curr Atheroscler Rep. 2023;25:701–9. https://doi.org/10.1007/s11883-023-01140-z. source

      Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Olezarsen binds to the mRNA of ApoC-III, resulting in increased destruction and decreased expression of mRNA, leading to reduction of ApoC-III level and ultimately decreases triglycerides levels.

    “It binds to the mRNA of ApoC-III resulting in the increased destruction and decreased expression of mRNA.This leads to reduction of ApoC-III level and ultimately decreases the triglycerides levels [1,7].”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [1] Mikhail N. Appraisal of olezarsen for treatment of hypertriglyceridemia. Int J Endovasc Treat Innov Tech. 2024;5:41–8. source

      The Introduction identifies olezarsen as an antisense oligonucleotide targeting APOC3 mRNA, and the Effects section says it inhibits APOC3 mRNA expression and lowers ApoC3 levels. The Abstract links reduced ApoC3 synthesis to lower triglycerides. Our copy does not state that olezarsen increases destruction of the mRNA; page numbers are unavailable. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites [7] Mikhail N. Appraisal of olezarsen for treatment of hypertriglyceridemia. Int J Endovasc Treat Innov Tech. 2024;5:41–8. https://doi.org/10.6179/ijetit.v5i1.334. source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    ApoC-III is a key regulator of triglyceride metabolism, and its inhibition has been proven effective in lowering triglyceride levels in preclinical studies and early clinical trials.

    “ApoC-III is a key regulator of triglyceride metabolism, and its inhibition has been proven effective in lowering triglyceride levels in preclinical studies and early clinical trials.”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [1] Mikhail N. Appraisal of olezarsen for treatment of hypertriglyceridemia. Int J Endovasc Treat Innov Tech. 2024;5:41–8. source

      The Introduction describes ApoC-III’s role in raising triglycerides, and the section on olezarsen in patients at high cardiovascular risk reports substantial triglyceride reductions in phase 2 trials (page numbers unavailable). The passages do not report triglyceride-lowering efficacy in preclinical studies, so that part of the claim is unsupported by our copy. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [6] Valdivielso P, Coca PI. Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen. Med. 2024;5:493–4. https://doi.org/10.1016/j.medj.2024.05.004. source

  • May combine two claims.

    Premisecitation

    Volanesorsen is effective in treating hypertriglyceridemia but is often associated with injection site reactions and a risk of thrombocytopenia, requiring regular platelet monitoring.

    “While Volanesorsen is effective in treating hypertriglyceridemia, it is often associated with injection site reactions and a risk of thrombocytopenia, requiring regular platelet monitoring [9].”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [9] Kolovou G, Kolovou V, Katsiki N. Volanesorsen: a new era in the treatment of severe hypertriglyceridemia. J Clin Med. 2022;11:982. https://doi.org/10.3390/jcm11040982. source

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Findingown data

    Among the participants, 101 received 50 mg, 79 received 80 mg, 22 received 10 mg, and 6 received 60 mg of Olezarsen every 4 weeks, while 90 were in the placebo group.

    “Among these, 101 received 50 mg, 79 were given 80 mg, 22 took 10 mg, and 6 were administered 60 mg of Olezarsen every 4 weeks, while 90 participants were in the placebo group.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    The risk ratios for any adverse events and serious adverse events were comparable between Olezarsen and control groups.

    “Specifically, the risk ratios (RR) for any adverse events (RR 0.96, 95% CI 0.87-1.05)and serious adverse events (RR 0.94, 95% CI 0.44-2.03)were comparable.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductown data

    Two independent authors screened the retrieved references based on title, abstracts and relevant outcomes and assessed eligibility, with a third independent reviewer resolving discrepancies.

    “The retrieved references were screened based on title, abstracts and relevant outcomes and assessed for eligibility on predefined inclusion and exclusion criteria by two independent authors (R.D. and R.T.).A third independent reviewer (M.N.S.) was employed to resolve any discrepancy.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductcitation

    Risk of bias of included studies was assessed using RoB 2.0 software by the Cochrane Collaboration.

    “The risk of bias of the included studies in five domains i.e. selection bias, performance bias, detection bias, attrition bias and reporting bias was assessed using RoB 2.0 software by the Cochrane Collaboration [14].”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [14] Chandler J, McKenzie J, Boutron I, Welch V. Cochrane methods 2016. Wiley. 2016. https://doi.org/10.1002/14651858.CD201601. source

  • May combine two claims.

    Interpretationown data

    Olezarsen is effective in managing hypertriglyceridemia patients with no significant adverse events.

    “Olezarsen is proved to be effective in managing hypertriglyceridemia patients with no significant adverse events.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductown data

    Data were extracted by two independent reviewers, with a third independent reviewer resolving discrepancies.

    “The data of the included studies was extracted by two independent reviewers (S.H. and P.S.) regarding study characteristics, intervention, comparison, and study outcomes.”
    • Also stated in: § 2.4 Data extraction and quality assessment · plain
      “A third independent reviewer (A.R.) was employed to resolve any discrepancy.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Both Olezarsen and Plozasiran have demonstrated efficacy in reducing plasma apoC-III and triglyceride levels.

    “Both have demonstrated efficacy in reducing plasma apoC-III and triglyceride levels [22].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [22] Chebli J, Larouche M, Gaudet D. APOC3 siRNA and ASO therapy for dyslipidemia. Curr Opin Endocrinol Diabetes Obes. 2024;31:70–7. https://doi.org/10.1097/MED.0000000000000857. source

  • May combine two claims.

    Interpretationown data

    Olezarsen significantly reduces triacylglycerol, total cholesterol, and VLDL levels in hypertriglyceridemia patients.

    “Our systematic review and meta-analysis highlight the efficacy of Olezarsen to significantly reduce triacylglycerol, total cholesterol, and VLDL levels in hypertriglyceridemia patients”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Study design and conductown data

    This meta-analysis incorporates high-quality RCTs with minimal risk of bias and low heterogeneity across studies.

    “Our meta-analysis incorporates high-quality RCTs with minimal risk of bias and low heterogeneity across studies.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    The favorable safety profile of Olezarsen can be attributed to its ASO-GalNAC3 conjugate design, which ensures targeted delivery to hepatocytes and reduced systemic exposure, resulting in low immunogenicity and reduced hypersensitivity and thrombocytopenia.

    “This favorable safety profile can be attributed to ASO-GalNAC3 conjugate design of Olezarsen which ensures targeted delivery of the drug to the hepatocytes and reduced systematic exposure resulting in low immunogenicity and reduced hypersensitivity and thrombocytopenia [8].”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [8] Gaudet D, Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S, et al. RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia. NEJM Evid. 2023. https://doi.org/10.1056/EVIDoa2200325. source

  • May combine two claims.

    Interpretationown data

    Olezarsen has an improved safety profile and no notable liver-related adverse effects in comparison to other apoC-III inhibitors, such as Plozasiran and Volanesorsen.

    “with improved safety profile and no notable liver-related adverse effects in comparison to other apoC-III inhibitors, such as Plozasiran and Volanesorsen.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The primary apo C-III inhibitors in advanced clinical development are GalNAc-ASO Olezarsen and ARO-APOC3 Plozasiran.

    “The primary apo C-III inhibitors in advanced clinical development are GalNAc-ASO Olezarsen and ARO-APOC3 Plozasiran.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [22] Chebli J, Larouche M, Gaudet D. APOC3 siRNA and ASO therapy for dyslipidemia. Curr Opin Endocrinol Diabetes Obes. 2024;31:70–7. https://doi.org/10.1097/MED.0000000000000857. source

  • May combine two claims.

    Interpretationown data

    Unlike Plozasiran, which is associated with mild to moderate elevations in liver transaminases, this study found no such liver-related adverse effects with Olezarsen, indicating a superior safety and tolerability profile.

    “However, unlike Plozasiran, which is associated with mild to moderate elevations in liver transaminases [8], our study found no such liver-related adverse effects with Olezarsen, indicating a superior safety and tolerability profile.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [8] Gaudet D, Clifton P, Sullivan D, Baker J, Schwabe C, Thackwray S, et al. RNA interference therapy targeting apolipoprotein C-III in hypertriglyceridemia. NEJM Evid. 2023. https://doi.org/10.1056/EVIDoa2200325. source
18 of 18

  • The paper relies on this without support.

    The safety and efficacy of Olezarsen in hypertriglyceridemia remain unexplored.

    “Previous studies highlight the triglyceride-lowering potential of Olezarsen, yet its safety and efficacy in hypertriglyceridemia remain unexplored.”

  • The paper relies on this without support.

    Olezarsen has a relatively better safety profile with no major adverse events compared to Volanesorsen.

    “Compared to its predecessor, Volanesorsen, which cause thrombocytopenia and injection site reactions, Olezarsen has a relatively better safety profile with no major adverse events.”
2 of 2

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • LDL result is called significant despite a confidence interval crossing zero

    Major

    The reported LDL mean-change confidence interval runs from −12.649% to 8.146%, including zero, yet the result is called significant and assigned P = 0.000. This also conflicts with the claim that all efficacy outcomes were significant.

  • Inconsistent participant totals for the four trials

    Major

    The results describe 202 olezarsen and 172 placebo patients (374 total), whereas the discussion describes 298 participants, including 208 assigned to olezarsen doses and 90 to placebo.

  • Discussion claims low heterogeneity despite high reported I2 values

    Major

    The discussion calls heterogeneity low, whereas the results explicitly call it very high and report efficacy-outcome I2 values ranging from 89.87% to 99.7%.

  • Alexander study year differs across tables

    Minor

    Table 3 dates the included Alexander study to 2019, while Table 2 dates the study with the same citation number to 2024.

  • Apo C-III confidence-interval endpoint differs between abstract and results

    Minor

    For the same −65.38% Apo C-III estimate, the abstract gives an upper confidence limit of −55.55%, while the results give −55.77%.

  • Control-group count differs between tables

    Minor

    Table 1 lists 39 control patients for Bergmark et al., while Table 2 lists 78 for the same study. The tables do not explain why the study's control group doubles.

6 of 6

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Mikhail N. Appraisal of olezarsen for treatment of hypertriglyceridemia. Int J Endovasc Treat Innov Tech. 2024;5:41–8. https://doi.org/10.6179/ijetit.v5i1.334. · DOI

Cited by

Sorted by citations

Related

Authors
Saddique, M. N., Thapa, R., Khan, Y., Javaid, H., Khawar, M. M., Rehman, A., Dave, R., Raval, R., Hejmadi, S., Singh, P., Rodriguez, P. R. T., Hussain, M., Raza, H., Ahmed, S., Shamoon, S., & Iqbal, J.
Affiliations
  • King Edward Medical University (PK)
  • Crozer-Keystone Health System (US)
  • Khyber Medical University (PK)
  • Ayub Medical College (PK)
  • B.J. Medical College (IN)
  • Nepalese Army Institute of Health Services (NP)
  • Universidad Privada del Valle (BO)
  • Services Institute of Medical Sciences (PK)
  • International University of Kyrgyzstan (KG)
  • Rawalpindi Medical University (PK)
  • Hamad Medical Corporation (QA)
Corresponding author
Iqbal, Javed
ORCID
Venue
Discover Medicine
Publisher
Springer Science and Business Media LLC
Published
2025-05-06
Volume
2
Issue
1
ISSN
3004-8885 (ISSN-L)
DOI
10.1007/s44337-025-00329-2
OpenAlex
W4410122404
Semantic Scholar
c1b08ae44915802b64053a2a783533133745e1ef
Cited by
6
References
17
Citations by year
2026: 4 · 2025: 2
FWCI
1.94
Type
journal article
Language
en
Open access
Licence
Locations
Discover Medicine (publishedVersion, cc-by-nc-nd)
Funders
Qatar National Library
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
olezarsen, hypertriglyceridemia, antisense oligonucleotides, apolipoprotein C-III, triglycerides, apolipoprotein B, HDL cholesterol, total cholesterol, cardiovascular risk, drug safety, adverse events, drug efficacy, severe hypertriglyceridemia, dyslipidemia management, lipoprotein metabolism, triglyceride-rich lipoproteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-19.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-19.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review